Effects of bariatric surgery on the medication irbesartan
Bariatric Surgery and Pharmacokinetics Irbesartan: BAR-MEDS Irbesartan
Norwegian University of Science and Technology · NCT03476603
This study looks at how bariatric surgery affects the way the body processes the medication irbesartan in patients getting ready for surgery.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 12 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | Norwegian University of Science and Technology (other) |
| Locations | 1 site (Trondheim) |
| Trial ID | NCT03476603 on ClinicalTrials.gov |
What this trial studies
This observational study investigates how bariatric surgery, specifically gastric bypass and sleeve gastrectomy, affects the pharmacokinetics of the medication irbesartan. It aims to understand changes in gastric pH, gastric emptying time, and gastrointestinal transit-time that may influence the biological availability of this drug. The study is conducted in Central Norway and focuses on patients preparing for these surgical procedures. By analyzing these pharmacokinetic changes, the research seeks to provide insights into medication management post-surgery.
Who should consider this trial
Good fit: Ideal candidates are Norwegian citizens preparing to undergo gastric bypass or sleeve gastrectomy.
Not a fit: Patients who have previously undergone resections in the gastrointestinal tract may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved medication management for patients undergoing bariatric surgery.
How similar studies have performed: While there is limited information on similar studies, the investigation into pharmacokinetics post-bariatric surgery is a relatively novel area.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Preparing to undergo gastric bypass or sleeve gastrectomy in Central Norway * Being a Norwegian citizen Exclusion Criteria: * Having previously undergone resections in the GI-tract
Where this trial is running
Trondheim
- St. Olavs University Hospital — Trondheim, Norway (RECRUITING)
Study contacts
- Principal investigator: Magnus Strømmen, MSc — St. Olavs Hospital
- Study coordinator: Magnus Strømmen, MSc
- Email: magnus.strommen@stolav.no
- Phone: 0047 72829970
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Obesity, Morbid, Bariatric surgery, Gastrointestinal tract, Biological availability, Pharmacokinetics, Irbesartan